Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	30.31	22.12	8.18
Research & Development	94.79	60.94	28
Total Operating Expenses	125.1	83.06	36.18
Operating Income	-125.1	-83.06	-36.18
Interest Income	13.62	12.14	2.53
Other Non-Operating Income (Expense)	-	-7.39	-1.12
Total Non-Operating Income (Expense)	13.62	4.75	1.4
Pretax Income	-111.48	-78.31	-34.78
Provision for Income Taxes	-	-	0.01
Net Income	-111.48	-78.31	-34.79
Net Income to Common	-111.48	-78.31	-34.79
Shares Outstanding (Basic)	39	21	2
Shares Outstanding (Diluted)	39	21	2
Shares Change (YoY)	87.74%	1277.26%	-
EPS (Basic)	-2.86	-3.78	-23.10
EPS (Diluted)	-2.86	-3.78	-23.10
Shares Outstanding	47.77	36.58	-
Free Cash Flow	-88.09	-67.23	-28.82
Free Cash Flow Per Share	-2.26	-3.24	-19.14
EBITDA	-124.08	-82.22	-36.07
EBIT	-125.1	-83.06	-36.18
Effective Tax Rate	0.00%	0.00%	-0.03%

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q